Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17013348 | 0.90 | MAPT (0.36) | REN | |
| SCHEMBL15599789 | 0.90 | LMNA (0.37) | REN | |
| SCHEMBL17013306 | 0.88 | GAA (0.37) | — | |
| SCHEMBL17013300 | 0.88 | REN (0.36) | TRPV4REN | |
| SCHEMBL17013352 | 0.84 | REN (0.38) | REN | |
| SCHEMBL17013309 | 0.84 | TDP1 (0.40) | REN | |
| SCHEMBL17013299 | 0.83 | NPC1 (0.37) | REN | |
| SCHEMBL17013305 | 0.82 | AVPR1B (0.42) | — | |
| SCHEMBL17013298 | 0.81 | MC4R (0.37) | REN | |
| SCHEMBL17013310 | 0.81 | SMYD2 (0.38) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | TEAD1 4099/4885ALOX5 2274/4885EPHX2 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.